Annexon Biosciences, Inc. (ANNX)
NASDAQ:ANNX
ANNX Stock Chart & Stats
$5.36
-$0.26(-5.25%)
At close: 4:00 PM EST
$5.36
-$0.26(-5.25%)
Day’s Range― - ―
52-Week Range$1.29 - $7.18
Previous CloseN/A
Volume252.73K
Average Volume (3M)2.92M
Market Cap
$860.14M
Enterprise Value$505.18M
Total Cash (Recent Filing)$238.34M
Total Debt (Recent Filing)$26.20M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding160,474,330
10 Day Avg. Volume3,425,113
30 Day Avg. Volume2,921,435
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-553.92
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$15.40Price Target Upside187.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated MechanismVonaprument's C1q-targeted action that protects photoreceptors and operates earlier in disease progression may enable real improvements in vision that set it apart from existing treatments.
Regulatory StrategyA coordinated plan targeting approvals in both the United States and Europe could broaden patient access and substantially increase the therapy's commercial opportunity.
Trial Execution IntegrityCompletion of ARCHER II enrollment, consistent event tracking, strong patient retention, and a data safety monitoring board recommendation to continue support confidence in the pivotal trial's data quality.
Bears Say
Binary Trial RiskDependence on a single late-stage study creates a binary outcome risk that could drive sharp share-price moves if results are negative or inconclusive.
Indication And Design UncertaintyGeographic atrophy is a clinically challenging indication and remaining uncertainties around the ARCHER II trial design and readout increase execution and commercial risk for the program.
Unconfirmed Clinical BenefitObserved visual acuity improvements were not accompanied by clear reductions in lesion growth, leaving the therapy's overall clinical benefit unconfirmed without larger confirmatory evidence.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences, Inc.’s price range in the past 12 months?
Annexon Biosciences, Inc. lowest stock price was $1.28 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences, Inc.’s market cap?
Annexon Biosciences, Inc.’s market cap is $860.14M.
When is Annexon Biosciences, Inc.’s upcoming earnings report date?
Annexon Biosciences, Inc.’s upcoming earnings report date is May 18, 2026 which is in 45 days.
How were Annexon Biosciences, Inc.’s earnings last quarter?
Annexon Biosciences, Inc. released its earnings results on Mar 30, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.313 by $0.033.
Is Annexon Biosciences, Inc. overvalued?
According to Wall Street analysts Annexon Biosciences, Inc.’s price is currently Undervalued.
Does Annexon Biosciences, Inc. pay dividends?
Annexon Biosciences, Inc. does not currently pay dividends.
What is Annexon Biosciences, Inc.’s EPS estimate?
Annexon Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annexon Biosciences, Inc. have?
Annexon Biosciences, Inc. has 160,474,330 shares outstanding.
What happened to Annexon Biosciences, Inc.’s price movement after its last earnings report?
Annexon Biosciences, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.313. Following the earnings report the stock price went up 11.694%.
Which hedge fund is a major shareholder of Annexon Biosciences, Inc.?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.40 (187.31% Upside)
$15.40 (187.31% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $313.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
196.13%
12-Months-Change
Fundamentals
Return on Equity
-102.24%
Trailing 12-Months
Asset Growth
-20.71%
Trailing 12-Months
Company Description
Annexon Biosciences, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$15.40
▲(187.31% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.59% Insiders
16.98% Mutual Funds
43.99% Other Institutional Investors
19.77% Public Companies and
Individual Investors